Review decision - January 2015

Review of NICE Technology Appraisal Guidance No.288; Dapagliflozin for the treatment of type 2 diabetes

Decision to defer the review

The planned date for review of the above guidance was December 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

NICE is currently developing a clinical guideline for type 2 diabetes, which has an anticipated publication date of August 2015.

It is appropriate to consider the recommendations made in TA288 in light of the recommendations made in the clinical guideline. Consequently we have decided to defer the consideration of the review of TA288 and that it will take place within 6 months of the publication of the clinical guideline, so that the Institute can make an informed decision as to how, if at all, the appraisal should be updated.

January 2015

This page was last updated: